OBJECTIVE: EphA2 overexpression predicts poor prognosis in endometrial cancer. To explore mechanisms for this association and assess its potential as therapeutic target, the relationship of EphA2 expression to markers of angiogenesis was examined using patient samples and an orthotopic mouse model of uterine cancer. EXPERIMENTAL DESIGN: Expression of EphA2, estrogen receptor (ER), progesterone receptor (PR), Ki-67, vascular endothelial growth factor (VEGF) and microvessel density (MVD) was evaluated using immunohistochemistry in 85 endometrioid endometrial adenocarcinomas (EEC) by two independent investigators. Results were correlated with clinicopathological characteristics. The effect of EphA2- agonist monoclonal antibody EA5, alone or in combination with docetaxel was studied in vitro and in vivo. Samples were analyzed for markers of angiogenesis, proliferation and apoptosis. RESULTS: Of 85 EEC samples, EphA2 was overexpressed in 47% of tumors and was significantly associated with high VEGF expression (p=0.001) and high MVD counts (p=0.02). High EphA2 expression, high VEGF expression and high MVD counts were significantly associated with shorter disease-specific survival. EA5 led to decrease in EphA2 expression and phosphorylation in vitro. In the murine model, while EA5 (33-88%) and docetaxel (23-55%) individually led to tumor inhibition over controls, combination therapy had the greatest efficacy (78-92%, p.
OBJECTIVE:EphA2 overexpression predicts poor prognosis in endometrial cancer. To explore mechanisms for this association and assess its potential as therapeutic target, the relationship of EphA2 expression to markers of angiogenesis was examined using patient samples and an orthotopic mouse model of uterine cancer. EXPERIMENTAL DESIGN: Expression of EphA2, estrogen receptor (ER), progesterone receptor (PR), Ki-67, vascular endothelial growth factor (VEGF) and microvessel density (MVD) was evaluated using immunohistochemistry in 85 endometrioid endometrial adenocarcinomas (EEC) by two independent investigators. Results were correlated with clinicopathological characteristics. The effect of EphA2- agonist monoclonal antibody EA5, alone or in combination with docetaxel was studied in vitro and in vivo. Samples were analyzed for markers of angiogenesis, proliferation and apoptosis. RESULTS: Of 85 EEC samples, EphA2 was overexpressed in 47% of tumors and was significantly associated with high VEGF expression (p=0.001) and high MVD counts (p=0.02). High EphA2 expression, high VEGF expression and high MVD counts were significantly associated with shorter disease-specific survival. EA5 led to decrease in EphA2 expression and phosphorylation in vitro. In the murine model, while EA5 (33-88%) and docetaxel (23-55%) individually led to tumor inhibition over controls, combination therapy had the greatest efficacy (78-92%, p.
Authors: Dana M Brantley; Nikki Cheng; Erin J Thompson; Qing Lin; Rolf A Brekken; Philip E Thorpe; Rebecca S Muraoka; Douglas Pat Cerretti; Ambra Pozzi; Dowdy Jackson; Charles Lin; Jin Chen Journal: Oncogene Date: 2002-10-10 Impact factor: 9.867
Authors: Nikki Cheng; Dana Brantley; Wei Bin Fang; Hua Liu; William Fanslow; Douglas Pat Cerretti; Katrin N Bussell; Alastair Reith; Dowdy Jackson; Jin Chen Journal: Neoplasia Date: 2003 Sep-Oct Impact factor: 5.715
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Premal H Thaker; Michael Deavers; Joseph Celestino; Angela Thornton; Mavis S Fletcher; Charles N Landen; Michael S Kinch; Peter A Kiener; Anil K Sood Journal: Clin Cancer Res Date: 2004-08-01 Impact factor: 12.531
Authors: Duangmani Thanapprapasr; Rebecca A Previs; Wei Hu; Cristina Ivan; Guillermo N Armaiz-Pena; Piotr L Dorniak; Jean M Hansen; Rajesha Rupaimoole; Jie Huang; Heather J Dalton; Rouba Ali-Fehmi; Robert L Coleman; Anil K Sood Journal: Mol Cancer Ther Date: 2015-04-01 Impact factor: 6.261
Authors: Michael J Wagner; Rahul Mitra; Mark J McArthur; Wallace Baze; Kirstin Barnhart; Sherry Y Wu; Cristian Rodriguez-Aguayo; Xinna Zhang; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood Journal: Mol Cancer Ther Date: 2017-03-06 Impact factor: 6.261
Authors: Jie Huang; Wei Hu; Justin Bottsford-Miller; Tao Liu; Hee Dong Han; Behrouz Zand; Sunila Pradeep; Ju-Won Roh; Duangmani Thanapprapasr; Heather J Dalton; Chad V Pecot; Rajesh Rupaimoole; Chunhua Lu; Bryan Fellman; Diana Urbauer; Yu Kang; Nicholas B Jennings; Li Huang; Michael T Deavers; Russell Broaddus; Robert L Coleman; Anil K Sood Journal: Clin Cancer Res Date: 2014-01-31 Impact factor: 12.531
Authors: Yutuan Wu; Jie Huang; Cristina Ivan; Yunjie Sun; Shaolin Ma; Lingegowda S Mangala; Bryan M Fellman; Diana L Urbauer; Nicholas B Jennings; Prahlad Ram; Robert L Coleman; Wei Hu; Anil K Sood Journal: Gynecol Oncol Date: 2021-08-11 Impact factor: 5.304
Authors: Xiyin Wang; Jillian R H Wendel; Robert E Emerson; Russell R Broaddus; Chad J Creighton; Douglas B Rusch; Aaron Buechlein; Francesco J DeMayo; John P Lydon; Shannon M Hawkins Journal: Oncogene Date: 2020-08-25 Impact factor: 9.867
Authors: Ingfrid S Haldorsen; Mihaela Popa; Tina Fonnes; Njål Brekke; Reidun Kopperud; Nicole C Visser; Cecilie B Rygh; Tina Pavlin; Helga B Salvesen; Emmet McCormack; Camilla Krakstad Journal: PLoS One Date: 2015-08-07 Impact factor: 3.240